Pharmakon moves to Cali; Salix seeks funds;

> Pharmakon, an Indiana-based pharmaceutical supplier providing medications to psychiatric hospitals and long-term care facilities, will move its headquarters to Carmel next year and will be adding employees in the process. Report

> Salix Pharmaceuticals, which specialized in gastrointestinal medications, said its cash reserves were down to $90 million as of June, and so the company is hoping to raise $50 million to expand its product lineup, increase revenue and counteract the pain from generic competitors. Report 

> Empire State Development Corporation is giving a state economic development grant of $175,000 to Chesapeake Pharmaceutical and Healthcare Packaging to help the company expand as well as to help alleviate some of the high costs of operating in New York.  Report

> Bayer HealthCare and Regeneron Pharmaceuticals say that their VEGF Trap-Eye drug candidate continues to show positive results in patients with macular regeneration during a mid-stage trial at 52 weeks. Report

> A 24-year-old student in Melbourne, Australia who was taking the contraceptive pill Yasmin for acne problems died yesterday, and some are blaming the pill, which she had been taking for about 4 months. Report

> Tiny nanotubes were used to precisely deliver a concentrated payload of chemotherapy directly to the site of a tumor, according to a team of scientists at Stanford University. Report

> The California Institute for Regenerative Medicine has handed out $59 million in research grants to 23 young scientists. Report

> The National Institutes of Health told staffers last week that it is setting up a bone marrow-stem cell transplant center within the National Institute for Arthritis and Musculoskeletal and Skin Diseases, according to an article in Wired. Report

> The pharmaceutical benefits manager Medco Health Solutions is partnering with the FDA to examine how genetic testing is coming into play to determine the right drug or dose for a patient. Release

> A new study conducted by researchers at Children's Hospital & Research Center Oakland shows that a century-old drug, methylene blue, may be able to slow or even cure Alzheimer's and Parkinson's disease. Report

And finally... There might be some hope for overcoming multiple drug resistance for antibiotics and chemotherapeutics, as researchers at Stanford University claim to have found a way around a common mechanism for resistance using a sort of arginine-rich transporter in the cells. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.